**Toujeo® (insulin glargine 300 units/mL)**  
**Guide for healthcare professionals**

**Key safety elements when switching to or from an insulin with a different strength**

This is supplied as a guide only. Healthcare professionals must refer to the Product Information for Toujeo before prescribing and dispensing the Toujeo SoloStar® pen, and advise patients to read the full instructions for use leaflet accompanying the pen.

**Important information on dosing when prescribing Toujeo®**

Toujeo SoloStar® is a prefilled pen that contains insulin glargine 300 units/mL. Toujeo® (insulin glargine 300 units/mL) and insulin glargine 100 units/mL are not bioequivalent and are therefore not interchangeable without dose adjustment.

The following information must be written on each prescription for Toujeo®

✔ Trade name and concentration: Toujeo® SoloStar® 300 units/mL
✔ Recommended daily dose in UNITS according to the scenarios outlined below

**The dose window of the Toujeo® SoloStar® pen shows the number of UNITS of Toujeo to be injected.**

**Initiation**

✔ Patients with type 1 diabetes mellitus: Toujeo® is to be used once-daily with meal-time insulin and requires subsequent individual dose adjustments

✔ Patients with type 2 diabetes mellitus: the recommended daily starting dose is 0.2 units/kg followed by individual dose adjustments

**Switch from insulin glargine 100 units/mL to Toujeo®**

✔ Switching from insulin glargine 100 units/mL to once-daily Toujeo® can be done on a unit-to-unit basis. A higher Toujeo® dose (approximately 10–18%) may be needed to achieve an individual’s target plasma glucose range

**Switch from other basal insulins to Toujeo®**

✔ Switching from once-daily basal insulins to once-daily Toujeo® can be done unit-to-unit based on the previous basal insulin dose

✔ Switching from twice-daily basal insulins to once-daily Toujeo®, the recommended initial Toujeo® dose is 80% of the total daily dose of basal insulin that is being discontinued

**When switching from an intermediate or long-acting insulin schedule to one that includes Toujeo®, a change in the dose of short-acting or fast-acting insulin analogue product may be required and the concomitant antihyperglycaemic treatment may need to be adjusted.**
Adjustments during the initial weeks

Dose adjustment may be needed when patients are switched to an insulin with a different strength.

Explain to your patient that Toujeo® is not the same as other basal insulins (including insulin glargine 100 units/mL) and that they must not switch between them without consulting a healthcare professional to adjust the dose. Blood glucose monitoring by patients is needed during the switch and the initial weeks thereafter.

The Toujeo® dose regimen (dose and timing) should be adjusted according to individual response to treatment. In clinical trial setting, after initial titration, on average, a 10-18% higher dose was needed to achieve target ranges for plasma glucose levels when using Toujeo® compared to the 100 units/mL formulation.

Close blood glucose monitoring is recommended during the switch and in the initial weeks thereafter.

Switch from Toujeo® to insulin glargine 100 units/mL or other basal insulin products

When switching from Toujeo to insulin glargine 100 units/mL, the dose should be reduced (approximately by 20%) to reduce the risk of hypoglycaemia. Close blood glucose monitoring is recommended during the switch and in the initial weeks thereafter.

Refer to Toujeo® Product Information for full prescribing recommendations.

Give a patient guide to your patient and recommend he/she must read it carefully, as well as the instructions for use leaflet provided in the Toujeo® Solostar® packaging.

Reporting adverse events: Please report medication errors or any side effects suspected to be associated with the use of Toujeo® SoloStar® pen to Sanofi, by telephone on 1800 818 806 or email medinfo.australia@sanofi.com


Minimum Product Information Toujeo (insulin glargine) Indications: Treatment of diabetes mellitus in adults. Contraindications: Hypersensitivity to insulin glargine or any of the excipients. Precautions: Not recommended for treatment of diabetic ketoacidosis; hypoglycaemia; switching between insulin glargine 100 U/mL and Toujeo; switching between other insulins and Toujeo; intercurrent illness; insulin antibodies; insulin label must always be checked before each injection to avoid medication errors between Toujeo and other insulins; pregnancy category B3; lactation; careful glucose monitoring and dose adjustments may be necessary in elderly patients; not studied in children; renal and hepatic impairment. Interactions: Oral antidiabetic medicinal products; cardiovascular, analgesic, anti-inflammatory, neurological, antipsychotic agents (see full PI); antibiotics; corticosteroids, other hormonal therapies (see full PI); diuretics; protease inhibitors; sympathomimetic agents; lithium; alcohol; sympatholytics including β-blockers; others, see full PI. Adverse Effects: Hypoglycaemia; visual impairment; injection site reactions; others, see full PI. Dosage and Administration: Subcutaneous, once daily. Not for intravenous use. Dose adjustment may be required e.g. if patient’s weight or life-style changes or change in timing of insulin dose. The desired blood glucose levels as well as doses and timing of anti-diabetic medication must be determined and adjusted individually. Instruct patients to never re-use a needle. Toujeo must not be drawn from the cartridge of the pre-filled pen into a syringe. Insulin glargine 100 U/mL and Toujeo are not bioequivalent and are not directly interchangeable. Toujeo must not be diluted or mixed with any other insulin products. When switching from insulin glargine 100 U/mL or other basal insulin products to Toujeo, dose may need to be adjusted. Close metabolic monitoring is recommended during the switch and in the initial weeks thereafter.

Reference: 1. Toujeo Approved Product Information.

PBS information: This product is not listed on the PBS.

Please review Product Information before prescribing Toujeo.


© Toujeo is a registered trademark of sanofi-aventis australia pty ltd.

Sanofi-aventis australia pty ltd trading as Sanofi, ABN 31 008 558 807, Talavera Corporate Centre, Building D, 12–24 Talavera Road, Macquarie Park, NSW 2113

SAVT016 Date of preparation: July 2015 SAANZ.TJO.15.04.0094w